GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications
Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Mohammed Eslam, Nahum Méndez-Sánchez · 2025
Read GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications by Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Mohammed Eslam, Nahum Méndez-Sánchez (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12739101.txt.
Description
Mariana Ramírez-Mejía and co-authors trace how sugar drugs that curb weight may raise gall ills. The study appeared in 2025. The drugs aid sugar and weight by steps that lift one gut call, cut its pair, and slow the gut. Long use and high dose tie to more gall stones and gall sac flare.
Paths in view span a hushed gut call that once spurred gall flow, bile salt paths, and gut-brain links. Each could let stones form in a still sac. The team then lays out a first care chart to cut that risk in folks on the drugs. Dose and time frame the risk call.
Catalog record
| CREATOR | Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Mohammed Eslam, Nahum Méndez-Sánchez |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |